Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Granules India Next On PE Buy List?

EIR Obtained For Chantilly, US Facility

Executive Summary

A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for PE funds.

You may also be interested in...



Advent Gains High-Potential ART Business Through Bharat Buy

With a majority stake in Bharat Serums, Advent gains access to biologics in gynecology and high-potential assisted reproductive technology. The deal also provides an exit to two other PE funds - OrbiMed and Kotak.

Granules Eyes Oncology After Exiting Ventures

Granules India has ambitions to become a vertically integrated player in cancer therapies after the company ended joint ventures for contract research and manufacturing services as well as for making bulk ibuprofen.

Vildagliptin Prices Fall By Over 70% In India Post Patent Expiry

Vildagliptin formulation prices fall by over 70% following the expiry of a patent held by Novartis in India. The innovator, meanwhile, is cashing in on co-marketing agreements with Indian partners like USV and Cipla

Topics

Related Companies

UsernamePublicRestriction

Register

SC141271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel